Summary and outlook of the pharmaceutical equipment industry in the first three quarters of 2021

The third quarter of 2021 has ended.
Looking back at the first three quarters of this year, how is the development of the pharmaceutical equipment industry? The author will briefly summarize and forecast the domestic pharmaceutical equipment industry in the first three quarters from the aspects of policy, performance, and industry
.
Pharmaceutical equipment (picture source: Pharmaceutical Net) Summary Policy: The pharmaceutical equipment industry is the upstream of the pharmaceutical industry and is indirectly affected by the relevant policies of the pharmaceutical industry
.
Since the beginning of this year, policies favorable to the pharmaceutical equipment industry have been continuously released, bringing new development opportunities to the development of the industry
.
For example, under the "three-child concept", the demand for children's medicine is expected to grow, and the production capacity of related pharmaceutical companies will also usher in a new round of expansion and upgrade.
The industry believes that or indirectly brings development opportunities to the upstream pharmaceutical equipment industry; another example is Chinese medicine formula granules.
The end of the pilot work is imminent.
The pharmaceutical companies in the layout need to be prepared in terms of production capacity and production scale.
It is expected that the demand for equipment and production lines for traditional Chinese medicine formula granules will also usher in growth
.
Performance chapter: In the first three quarters of 2021, the overall performance of the pharmaceutical equipment industry is improving, especially in the first half of the year.
In the case of delayed delivery of imported equipment, most pharmaceutical machinery companies have continued their order growth since 2020.
The effect of the diversified layout of the few companies has appeared, which has doubled the semi-annual performance
.
For example, in the first half of 2021, Chutian Technology made a profit of approximately 236 million yuan, an increase of 1321.
22% year-on-year; Xinlai should make a profit of approximately 67.
89 million yuan, an increase of 101.
1% year-on-year; Tofflon's performance was also relatively bright, achieving a net return The profit was 340 million yuan, a year-on-year increase of 97.
74%
.
Industry chapter: Since the beginning of this year, industry companies have made continuous major moves, including speeding up internationalization, speeding up transformation and upgrading, etc.
, to further enhance their own competitiveness
.
Among them, many pharmaceutical machinery companies attach great importance to the international layout.
For example, Chutian Technology said in an institutional survey in July that in the next 3-5 years, the company plans to maintain an annual increase of 10%-20% in export business.
By about 2025, the export business income of Chutian headquarters will account for 40%-50% of the total revenue; Liaoning Chunguang plans to ensure that its products reach about 30% of the company's total sales within three years.

.
By 2025, we will strive to account for 50% of both international sales and domestic sales, so as to achieve a bigger and stronger situation at both ends
.
In terms of accelerating transformation and upgrading, for example, on September 27, Chutian Technology issued an announcement saying that in order to further supplement the biopharmaceutical-related equipment and product chain, and promote the company’s development from an “equipment-based” enterprise to a “technology-based” enterprise, Chutian Technology Co-invested with related parties to establish a company engaged in the main business of providing microspheres and filler media
.
Outlook From the perspective of the industry, the domestic pharmaceutical machinery industry is in a new round of development opportunities in 2021.
With the accelerated upgrading of the pharmaceutical industry and the rapid development of emerging fields such as monoclonal antibodies, a series of consistency evaluations and volume purchases will be added.
Favorable policy advancement, entering the fourth quarter, the pharmaceutical equipment industry is expected to continue its growth trend
.
Industrial Securities stated in a research report that the pharmaceutical equipment market has entered a growth period of overall stability and partial breakthroughs: With the recovery of the upstream pharmaceutical industry, the Chinese pharmaceutical equipment market is expected to reach US$4.
58 billion in 2025, with a compound growth rate of 8.
1%
.
It is worth mentioning that while seizing opportunities, domestically-made pharmaceutical machines still face challenges.
For example, in terms of internationalization, domestic enterprises generally have low level of equipment informatization and low competitiveness in the process of entering the international stage.
The problem: In the high-end field, the voice of domestic equipment needs to be improved urgently.
Domestic companies need to increase R&D investment and accelerate the transition from low-end to mid-to-high-end in order to be more competitive
.